Following on Iceland's success, countries now pursuing or planning national genome projects of varying scale, scope and rationale include the UK (via the UK Biobank as well as Genomics England and the Scottish Genomes Partnership separately); the US (All of Us as well as the Million Veteran Program), Australia, Canada, Dubai, Estonia, Finland, France, Hong Kong, Japan, Netherlands, Qatar, Saudi Arabia, Singapore, South Korea, Sweden, and Turkey. Projects funded either largely or partially by pharmaceutical companies to inform drug target discovery include FinnGen (partly led by Mark Daly), Regeneron/Geisinger, and Genomics Medicine Ireland.